Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 43

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 43
---
 Company and their interests may not be aligned with the interests of our other shareholders |

| ● | Risks relating to conduct substantially all of our operations outside the United States |

| ● | Risks relating to adopt certain home country practices or take advantage of certain reduced reporting requirements |

Risks Related to DiamiR

| ● | Risks related to not completing the DiamiR merger. |

| ● | Risks relating to researchers, clinicians and healthcare administrators not adopting DiamiR’s screening and diagnostic products |

| ● | Risks related to the long process associated with new product development and the inability to commercialize CogniMIR® or any other products including risks associated with obtaining reimbursement. |

| ● | Risks related to DiamiR having a sole supplier for some of the materials used in its tests and services. |

| ● | Risks related to DiamiR’s inability to enter into and maintain new clinical collaborations. |

| ● | Risks related to DiamiR’s clinical tests not performing as expected and being unable to achieve widespread market adoption among physicians. |

| ● | Risks associated maintaining and renewing licenses (CLIA and CAP) for DiamiR laboratory. |

| ● | Risks related to future changes in FDA oversight of LDTs. |

20 Implications of Being a Foreign Private Issuer The Company is considered a “foreign private issuer.” In its capacity as a foreign private issuer, the Company is exempted from certain rules under the U.S. Securities Exchange Act of 1934, as amended (“Exchange Act”), that impose certain disclosure obligations and procedural requirements for proxy solicitations under Section 14 of the Exchange Act. In addition, the Company’s officers, directors and principal shareholders are exempt from the reporting and “short-swing” profit recovery provisions of Section 16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our Class A Ordinary Shares. Moreover, the Company is not required to file periodic reports and financial statements with the U.S. Securities and Exchange Commission (“SEC”), as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. In addition, the Company is not required to comply with Regulation FD, which restricts the selective disclosure of material information. The Company may take advantage of these exemptions until such time as it is no longer a foreign private issuer. The Company would cease to be a foreign private issuer at such time when more than 50% of its outstanding voting securities are held by U